【rice krispies with karo syrup and peanut butter】Morgan Stanley Downgrades Hologic On Tough Cynosure Recovery, Surgery Business Risks
Although
Hologic,rice krispies with karo syrup and peanut butter Inc.
(NASDAQ:
HOLX
) acquired
Cynosure
to achieve a higher weighted average market growth rate, Cynosure's main businesses have not delivered as expected, according to Morgan Stanley.
The Analyst
Morgan Stanley’s David Lewis downgraded
Hologic
from
Equal-weight to Underweight
and cut the price target from $44 to $39.
The Thesis
Hologic diversified into aesthetics with its purchase of Cynosure, with expectations of generating higher WAMGR, Lewis said in the Wednesday downgrade note.
Yet MonaLisa Touch and SculpSure — which drove almost all of Cynosure’s growth prior to the acquisition — have not returned to their pre-acquisition levels, the analyst said.
The body sculpting channel is showing signs of saturation, and the company's women’s health strategy appears flawed given the FDA’s latest scrutiny of vaginal rejuvenation, Lewis said.
Competition for NovaSure will intensify if Channel Medsystem’s Cerene snags FDA approval in mid-2019, he said.
Hologic operates in slower growth end markets versus its peers and has a WAMGR of around 3.5 percent, which is significantly below that the competition's 5 percent, the analyst said.
“A structural 3-percent organic and 8-percent EPS growth profile is below peers at 5-6 percent organic and double-digit earnings growth, which suggests Hologic is likely to relatively underperform peers."
Price Action
Hologic shares were trading down 6.45 percent at $38.45 at the time of publication Wednesday.
Related Links:
Hologic Downgraded By BofA As Cynosure Headwinds Persist
Hologic: Meet Goldman Sach's New 'Conviction Buy'
Photo courtesy of Hologic.
Latest Ratings for HOLX
Jan 2019
Morgan Stanley
Downgrades
Equal-Weight
Underweight
Nov 2018
RBC Capital
Maintains
Sector Perform
Sector Perform
Oct 2018
Morgan Stanley
Maintains
Equal-Weight
Equal-Weight
View More Analyst Ratings for HOLX
View the Latest Analyst Ratings
See more from Benzinga
JPMorgan Sees Buying Opportunity In Torchmark
Analyst: NeuroMetrix Benefits From Alternative Pain Management Trend
Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
View comments
下一篇:CRON INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of a Filing Deadline in a Securities Class Action Against Cronos Group Inc.
相关文章:
- Global Care Capital Portfolio Company ViraxClear Secures Supply Contracts to Meet Demand for COVID-19 Antibody Test Kits in Europe and Singapore
- AMWD vs. WSC: Which Stock Should Value Investors Buy Now?
- CymaBay Therapeutics (NASDAQ:CBAY) Is In A Good Position To Deliver On Growth Plans
- British currency exchange WorldFirst shuts U.S. operations - FT
- NEWSMAKER-So near yet so far for Malaysia's Anwar
- S&P 500 Has Only Been This Expensive One Other Time — At The Peak Of The Dot-Com Bubble
- Q&A: O'Melveny Practice Leader Covers the Sports-Betting Blitz
- Tough Backdrop to Hurt Affiliated Managers (AMG) Q4 Earnings
- Is The Goldman Sachs Group (GS) Stock Outpacing Its Finance Peers This Year?
- Here is Why Growth Investors Should Buy Broadcom Inc. (AVGO) Now
相关推荐:
- Energy Fuels Inc.'s (TSE:EFR) Intrinsic Value Is Potentially 96% Above Its Share Price
- What To Know Before Buying Canadian Tire Corporation, Limited (TSE:CTC.A) For Its Dividend
- Japan fourth quarter capex points to upward revision to GDP but outlook weak
- Stock Prices Have Plummeted. That Doesn't Make Them Good Buys
- How to shop safe during a holiday season like no other
- SilverBow Resources, Inc. (SBOW) Q4 2018 Earnings Conference Call Transcript
- BRIEF-Atlinks Group Says Expected To Record A Loss For Year
- Do Directors Own LiveXLive Media, Inc. (NASDAQ:LIVX) Shares?
- Storms that slammed Central America in 2020 just a preview, climate change experts say
- Is Cembra Money Bank AG's (VTX:CMBN) High P/E Ratio A Problem For Investors?
- Despite Its High P/E Ratio, Is Ovzon AB (publ) (STO:OVZON) Still Undervalued?
- EMERGING MARKETS-Latam FX attempt comeback, Colombian peso eyes best day in 7 months
- Time To Worry? Analysts Are Downgrading Their Aubay Société Anonyme (EPA:AUB) Outlook
- Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
- Manganese X Receives Eligibility for DTC Trading in the U.S.
- EPR Properties: 3Q Earnings Snapshot
- Can Ero Copper Corp. (TSE:ERO) Maintain Its Strong Returns?
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Peabody Energy Corporation
- Suzan Craig and Tahi Restore Nature and Make 100 Percent Natural, Genuine Honey
- Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Groupon, Inc. (GRPN)